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Objective: To examine the effect of Pandanus amaryllifolius (P. amaryllifolius) leaf
extract on the insulin resistance state in obese ICR mice.
Methods: Obesity was induced in mice fed with high-fat diet (45% fat) for 12 weeks. After
the ﬁrst six weeks on the diet, the obese mice were administered with the water extract of
P. amaryllifolius leaf at 125 and 250 mg/kg/day, respectively for another six weeks. At the
5th week of treatment, oral glucose tolerance test was conducted. After six weeks of treat-
ment, the levels of blood glucose, serum insulin, leptin, adiponectin, and lipid proﬁles were
determined. The liver, muscle and epididymal fat tissues were removed for measuring the
biochemical parameters and protein expression, as well as histological examination.
Results: Six weeks of treatment with P. amaryllifolius led to a signiﬁcant reduction in
the blood glucose level as well as improvement in the insulin resistance. P. amaryllifolius
also increased the liver glycogen storage and serum adiponectin and decreased the serum
leptin levels. A reduction in the serum and hepatic triglyceride, and non-esteriﬁed fatty
acid levels was also observed. The histological examination showed that the obese mice
treated with P. amaryllifolius reduced the lipid droplet in liver tissue and adipocyte size in
epididymal fat tissue. The treatment also increased the protein expression of glucose
transporter 4 in the muscle and fat tissues.
Conclusions: The treatment with P. amaryllifolius could decrease several parameters of
impaired glucose and lipidmetabolism. To the best of our knowledge, this is theﬁrst report on
the role of P. amaryllifolius leaf extract in alleviating the insulin dysfunction in obesity state.1. Introduction
Obesity is one of the major risk factors for diabetes, hyper-
tension, dyslipidemia, and atherosclerosis [1,2]. The developmentof obesity is the etiology for inducing the status of insulin
resistance, which is a primary risk factor for type 2 diabetes
mellitus. The impaired insulin action in obesity can inhibit
glucose output from the liver and glucose uptake into the fat
and muscle cells [3].
Excessive lipid accumulation in the nonadipose tissues,
especially in the liver, can lead to the development of fatty liver
and insulin resistance. Fatty liver is a reversible condition that is
marked by increased accumulation of triglyceride (TG) in the
hepatocytes. The liver and adipose tissues have been found to
remain dysfunctional in obesity condition [4–6]. Adipose tissue
plays an important role in the regulation of energy
homeostasis and insulin resistance development. Long-term
high-fat diet (HFD) feeding can cause adipocyte hypertrophy
and its dysfunction, which is characterized by an excessive
release of free fatty acids into the circulation [7]. Adipose tissue
produces adipokine, including adiponectin, which is responsiblearticle under the CC BY-NC-ND license (http://
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and human subjects have shown that an increased plasma
adiponectin level can improve the insulin resistance [8–12].
Moreover, the glucose uptake and insulin sensitivity in
peripheral tissues are involved in the stimulation of glucose
transporter 4 (GLUT4) signaling cascade [13–17].
Pandanus amaryllifolius (P. amaryllifolius) is a tropical plant
found in India, South China, and Southeast Asia including
Thailand. It exhibits several bioactivities such as antiviral [18],
antioxidant [19], and antihyperglycemic activities [20]. However,
the effects of P. amaryllifolius leaf extract on the obesity-
induced insulin resistant state have not been clearly demon-
strated. Therefore, given the increasing incidence of obesity, the
aim of this study was to investigate the effect of P. amaryllifolius
leaf extract on impaired insulin sensitivity in HFD-fed mice.
2. Materials and methods
2.1. Plant extraction
The leaves of P. amaryllifolius were collected from Buriram,
Thailand between July and September 2013. A voucher specimen
(SKP 138 16 01 01) was deposited at the Faculty of Pharma-
ceutical Sciences, Prince of Songkla University, Thailand. The
dried leaves (100 g) were extracted three times with distilled water
(1 L) at 100 C for 30 min. This extract was concentrated and
subsequently freeze-dried. By using this procedure, the yield
obtained was 10.11% of the starting dry weight of the leaves. The
P. amaryllifolius extract obtained during this procedure was kept
at −20 C until further use.
2.2. Animals and induction of obesity
All experimental procedures involving animals were con-
ducted in accordance with the standards of Association for
Assessment and Accreditation of Laboratory Animal Care
(Frederick, MD, USA) and approved by the Animal Ethics
Committee, Faculty of Medicine, Thammasat University,
Thailand (Rec. No. AE 010/2014). Male ICR mice weighing 20–
25 g were purchased from the National Laboratory Animal
Center of Mahidol University, Nakhon Pathom, Thailand. They
were maintained in an air-conditioned room [(25 ± 2) C] with a
12 h light: 12 h dark cycle and fed with a low-fat diet and water
ad libitum for a week. After random selection, the mice were fed
with low-fat diet containing 10% fat (D12450H, Research Diets,
New Brunswick, NJ, USA) with a total energy of 3.85 kcal/g or
HFD containing 45% fat (D12451, Research Diets, New
Brunswick, NJ, USA) with a total energy of 4.73 kcal/g for 12
weeks.
2.3. Treatment design
After the completion of the ﬁrst six weeks on diets, the animals
were divided into four groupswith eightmice in each group. Group
1 consisted of normal control mice treated with 5% gum arabic;
Group 2 comprised obese controlmice treatedwith 5%gumarabic;
and Groups 3 and 4 consisted of obese mice treated with 125 and
250 mg/kg of P. amaryllifolius extracts, respectively. The doses
selection was based on our preliminary study, and the high blood
glucose was reduced in the obese mouse model after one-week
treatment with P. amaryllifolius extracts. The P. amaryllifoliusextracts were dissolved in 5% gum arabic. The body weight and
food intake of the mice were measured every week. After ﬁve
weeks of treatment, the mice were fasted for 6 h and orally
administered with glucose (2 g/kg) for oral glucose tolerance test
(OGTT). The blood glucose levels were determined from the tail
vein blood, before and after the glucose loading at regular intervals
of 20, 60, and 120 min.
2.4. Blood and tissue collection
After six weeks of treatment, the mice were fasted for 6 h and
sacriﬁced with isoﬂurane anesthesia. Whole blood samples were
collected from the heart for determining the blood glucose level,
and the remaining blood samples were centrifuged at 3000 r/min
for 10 min at 4 C. Subsequently, the serum was collected for
measuring the lipid proﬁles, insulin, leptin, and adiponectin
levels. The liver, gastrocnemius muscle, and epididymal fat
tissues were then removed for the determination of biochemical
parameters, protein expression, and histological examination.
2.5. Determination of serum insulin, leptin, and
adiponectin levels
After six weeks of treatment, the fasting serum insulin, leptin,
and adiponectin concentrations were measured using the ELISA
kit (EMD Millipore, Billerica, MA, USA).
2.6. Determination of serum and liver lipid proﬁles
After six weeks of the treatment with P. amaryllifolius ex-
tracts, the serum total cholesterol (TC), TG and non-esteriﬁed
fatty acid (NEFA), and liver TG levels were measured using
the enzymatic colorimetric kit (Wako, Osaka, Japan). The pro-
tocols for liver TG and NEFA extractions were used as
described previously [21].
2.7. Determination of hepatic glycogen synthesis
The glycogen content was determined as described previ-
ously [21]. Brieﬂy, the liver was homogenized in 30% KOH
solution. The homogenized liver was then dissolved in a
boiling water-bath (100 C) for 30 min and precipitated with
95% ethanol. The pellet was suspended in distilled water, mixed
with 0.2% anthrone reagent, and absorbance was measured at
620 nm.
2.8. Western blot
Plasma membrane proteins of skeletal muscle and epididymal
adipose tissues were homogenized and extracted in TPER® mixed
with Halt® protease inhibitor cocktail (Thermo Scientiﬁc, IL,
USA). The plasma membrane GLUT4 protein was separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis and
transferred to polyvinylidene diﬂuoride membranes. The mem-
branes were blocked and incubated with anti-GLUT4 and anti-
actin primary antibodies (dilution 1:200, Santa Cruz Biotech-
nology, Dallas, TX, USA). The membranes were incubated with
horseradish peroxidase-conjugated secondary antibody (dilution
1:2000, Santa Cruz Biotechnology, Dallas, TX, USA), and
immunoreactive bands were developed in Clarity™Western ECL
substrate (Bio-Rad, CA,USA). The band intensities were analyzed
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Bioscience, Lincoln, NE, USA).
2.9. Histological examination
Liver and epididymal fat tissues were ﬁxed with 10%
formalin and embedded in parafﬁn. The parafﬁn sections (3 mm)
were cut, mounted on glass slides and stained with hematoxylin
and eosin. The area of adipocyte was calculated using an ImageJ
software program (National Institute of Health, Bethesda, MD,
USA).
2.10. Statistical analyses
All data were expressed asmean± SEM, and statistical analysis
was performed using One-way ANOVA, followed by Tukey's
post hoc test. A value ofP< 0.05was considered to be statistically
signiﬁcant. The statistical analyses were performed using
computer-based software SigmaStat (Systat Software, CA, USA).
3. Results
3.1. Glucose and lipid metabolic parameters
After six weeks of treatment, the body weight of obese
control mice was found to be signiﬁcantly higher than that of
normal control mice (Figure 1A) (P < 0.05). The body weight of
obese mice treated with P. amaryllifolius extract at 125 and
250 mg/kg, respectively also followed an increasing trend. No
signiﬁcant difference in food intake was observed among the
groups (Figure 1B). The energy intake in obese mice treated
with 250 mg/kg P. amaryllifolius was signiﬁcantly increased as
compared to normal control mice (Figure 1C). However, the
epididymal fat weight in all obese groups was signiﬁcantly60
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Figure 1. Effect of P. amaryllifolius on body weight (A), food intake (B), energ
epididymal fat tissues (F) in HFD-induced obese mice.
Data are presented as mean ± SEM (n = 8). #: P < 0.05 when compared to nor
Normal control mice; OB: Obese control mice; OB + PA125: Obese mice treated
P. amaryllifolius at 250 mg/kg.increased as compared to normal control group (Figure 1D)
(P < 0.05). No reduction in the fat weight was observed in obese
mice treated with P. amaryllifolius extract. Interestingly, their
adipocyte size was signiﬁcantly smaller as compared to obese
control mice (Figure 1E,F) (P < 0.05).
After six weeks of treatment, the fasting blood glucose level of
obese control mice was found to be signiﬁcantly higher than that in
normal control mice (Figure 2A) (P < 0.05). Comparatively, a
signiﬁcant reduction in fasting blood glucose was observed in
obese mice treated with P. amaryllifolius extracts at 125 and
250 mg/kg, respectively (P < 0.05). Obese control mice showed a
high serum insulin level as compared to normal control mice
(Figure 2B), whereas a signiﬁcant reduction in insulin level was
noted inP. amaryllifolius-treated obesemice (P< 0.05). As shown
in Figure 2C, the P. amaryllifolius-treated obese mice showed
increased adiponectin levels as compared to obese control mice.
The serum leptin level of obese control mice was also found to be
signiﬁcantly higher than that of normal control mice (Figure 2D)
(P < 0.05) while obese mice treated with P. amaryllifolius at 125
and 250 mg/kg showed a signiﬁcant reduction in the leptin level as
compared to obese control mice (P < 0.05). In comparison to
normal control mice, the OGTT for obese control mice showed
signiﬁcantly higher levels of blood glucose in the fasting state and
during 120min after the glucose loading (Figure 2E) (P< 0.05). In
the case of P. amaryllifolius-treated obese mice, a signiﬁcant
reduction in the high blood glucose was observed at 60 and
120 min after glucose loading as compared to obese control mice
(P < 0.05). In addition, obese control mice showed a decreased
liver glycogen content as compared to normal control mice;
however, the treatment with P. amaryllifolius at 250 mg/kg
restored this reduction (Figure 2F).
No reduction in serum TC was observed even after six
weeks of treatment with P. amaryllifolius (Figure 3A). How-
ever, a signiﬁcant reduction (P < 0.05) in serum TG and NEFA25
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Figure 2. Effect of P. amaryllifolius on fasting blood glucose (A), serum insulin (B), serum adiponectin (C), serum leptin (D), blood glucose in OGTT (E),
and liver glycogen (F) in HFD-induced obese mice.
Data are presented as mean ± SEM (n = 8). #: P < 0.05 when compared to normal control mice. *: P < 0.05 when compared to obese control mice. NM:
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Suphaket Saenthaweesuk et al./Asian Pac J Trop Biomed 2016; 6(10): 866–871870was observed in the case of P. amaryllifolius-treated obese
mice (125 and 250 mg/kg) as compared to obese control mice
(Figure 3B,C). In addition, the treatment with P. amaryllifolius
signiﬁcantly decreased the accumulation of TG and NEFA in
the liver tissue (Figure 3D,E) (P < 0.05). The liver weight of
obese control mice increased as compared to normal control
mice, and the increased liver weight was signiﬁcantly reduced
after the treatment with P. amaryllifolius (Figure 3F)
(P < 0.05). In the case of liver histology, more lipid droplets
were found in obese control mice compared to those in the
P. amaryllifolius-treated obese mice (Figure 3G–J), which was
consistent with the results of liver TG and NEFA.
3.2. Protein expressions of plasma membrane GLUT4
The expressions of plasma membrane GLUT4 proteins in the
muscle and fat cells were signiﬁcantly reduced in obese control
mice (0.19- and 0.30-fold, respectively compared with the basal
level) (Figure 4A,B). However, treatment with 125 and 250 mg/kg
P. amaryllifolius signiﬁcantly increased the muscle GLUT4 pro-
tein by 0.78- and 0.88-fold of control, respectively when compared
with obese control group (Figure 4A). GLUT4 protein expression
in adipose tissue was also up-regulated by 0.68- and 0.81-fold after
treatment with 125 and 250 mg/kg P. amaryllifolius, respectively
(Figure 4B).1.2
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Figure 4. Effect of P. amaryllifolius on muscle (A) and fat (B) plasma membrane GLUT4 protein expressions in HFD-induced obese mice.
Data are presented as mean ± SEM (n = 8). #: P < 0.05 when compared to normal control mice. *: P < 0.05 when compared to obese control mice. NM:
Normal control mice; OB: Obese control mice; OB + PA125: Obese mice treated with P. amaryllifolius at 125 mg/kg; OB + PA250: Obese mice treated with
P. amaryllifolius at 250 mg/kg.4. Discussion
In the present study, HFD-induced insulin resistant state with
decreased glucose tolerance and insulin sensitivity and increased
insulin level in mice. This model also showed dyslipidemia and
increased hepatic fat accumulation. Furthermore, this model was
found to have reduced hepatic glycogen contents. Interestingly,
the treatment with P. amaryllifolius extract can signiﬁcantly
improve the conditions of hyperinsulinemia, glucose intolerance,
hyperlipidemia, and fatty liver in obese mice.
Insulin resistance is a characteristic feature of type 2 diabetes
mellitus development. This condition is related to hyperglycemia
and decreased glycogen synthesis in type 2 diabetes mellitus [22].
The present study showed a signiﬁcant reduction in hypergly-
cemia and improved insulin sensitivity in the P. amaryllifolius-
treated obese mice. Moreover, the treatment with P. amaryllifolius
also improved glucose metabolism by restoring glycogen
synthesis. Adipokines, such as leptin and adiponectin, are recogni-
zed as systemic factors affecting insulin sensitivity. The leptinlevel tends to be elevated and the adiponectin level is slightly
reduced in dietary obese rodents [23]. However, in this study, it
was observed that the serum leptin was signiﬁcantly reduced in
obese mice treated with P. amaryllifolius.
Moreover, the treated obese mice showed a signiﬁcant in-
crease in the serum adiponectin level. These results suggest that
this treatment may improve insulin resistance in HFD-induced
obese mice.
GLUT4 is considered to be the most important glucose
transporter in the peripheral tissues, such as the fat and muscle
cells. Improved GLUT4 function can control the blood glucose
level. However, the deﬁciency of insulin or insulin-resistant
condition plays a crucial role in the suppression of GLUT4
translocation, leading to decreased uptake of glucose into the fat
and muscle cells, which contributes signiﬁcantly to the elevated
glucose levels [24]. Obesity is strongly related to insulin
resistance that can lead to reduced GLUT4 expression in the
insulin-sensitive tissues [14,16]. Our results showed that the
treatment with P. amaryllifolius restored the decreased GLUT4
protein expression leading to enhanced glucose uptake into the
muscle and fat cells. This action could be useful in controlling
the hyperglycemic condition.
The cholesterol absorption from the small intestine shows
increased cholesterol level in HFD feeding [25]. The HFD model
can increase the risk of hypertriglyceridemia possibly due to theincreased absorption and formation of TG and decreased TG
uptake into the fat tissues [26]. Other studies showed that the
increased fat accumulation in the liver tissue and the elevated
circulating FFA are the indexes in insulin resistance cases
[27,28]. Although treatment with P. amaryllifolius could not
decrease the elevated serum TC, all doses of the treatment
effectively reduced the levels of serum TG and NEFA. Obese
mice treated with P. amaryllifolius also showed reduced liver
TG and NEFA levels with decreased fat accumulation in the
liver. The reduction of hyperlipidemia during treatment with
P. amaryllifolius could be the result of stimulated lipid storage
in fat tissue and suppressed TG and NEFA concentrations in
the serum and liver.
In conclusion, the administration of P. amaryllifolius
improved the insulin resistance in HFD-induced obese mice by
reducing the blood glucose level, stimulating insulin sensitivity,
decreasing serum and hepatic TG and NEFA, stimulating protein
expression of GLUT4, and reducing adipocyte size in epidid-
ymal fat tissues. Therefore, these results support the useful
Suphaket Saenthaweesuk et al./Asian Pac J Trop Biomed 2016; 6(10): 866–871 871action of treatment with P. amaryllifolius leaf extracts in the
improvement of insulin action in the obesity condition.
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